From: Migraine day frequency in migraine prevention: longitudinal modelling approaches
Negative binomial (Dispersion parameter 0.2397) | Beta-binomial (ICC 0.0297) | Poisson | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Covariate | Predicted MD Frequencya | 95% CI | FRR | 95% CI | P value | Â | Predicted MD Frequencya | 95% CI | Coefficient | 95% CI | P value | Â | Predicted MD Frequencya | 95% CI | FRR | 95% CI | P value |
Week 0 | 8.261 | (7.622, 8.900) | – | – | – | Week 0 | 7.944 | (7.334, 8.555) | – | – | – | Week 0 | 8.333 | (7.790, 8.877) | – | – | – |
Week 4 | 7.199 | (6.714, 7.684) | 0.746 | (0.712, 0.782) | < 0.001 | Week 4 | 7.081 | (6.595, 7.567) | −0.292 | (− 0.345, -0.239) | < 0.001 | Week 4 | 7.312 | (6.824, 7.800) | 0.768 | (0.737, 0.800) | < 0.001 |
Week 8 | 6.731 | (6.278, 7.185) | 0.693 | (0.661, 0.727) | < 0.001 | Week 8 | 6.672 | (6.215, 7.128) | −0.379 | (−0.433, -0.324) | < 0.001 | Week 8 | 6.847 | (6.385, 7.310) | 0.718 | (0.688, 0.749) | < 0.001 |
Week 12 | 6.4337 | (6.005, 6.862) | 0.651 | (0.620, 0.683) | < 0.001 | Week 12 | 6.386 | (5.952, 6.820) | −0.447 | (−0.503, -0.391) | < 0.001 | Week 12 | 6.555 | (6.108, 7.002) | 0.677 | (0.649, 0.706) | < 0.001 |
Week 24 | 6.421 | (6.002, 6.840) | 0.634 | (0.604, 0.666) | < 0.001 | Week 24 | 6.293 | (5.866, 6.720) | −0.486 | (−0.542, -0.429) | < 0.001 | Week 24 | 6.552 | (6.105, 6.998) | 0.662 | (0.634, 0.690) | < 0.001 |
Treatment (Erenumab vs Placebo) | 0.761 | (0.702, 0.825) | < 0.001 | Treatment (Erenumab vs Placebo) | −0.327 | (−0.362, -0.291) | < 0.001 | Treatment (Erenumab vs Placebo) | 0.764 | (0.705, 0.827) | < 0.001 | ||||||
RMSE | 0.075 | RMSE | 0.102 | RMSE | 0.142 | ||||||||||||
MAE | 0.246 | MAE | 0.336 | MAE | 0.466 |